Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

KPV vs VIP Which Better Comparison: Research Applications

Inflammatory Bowel Disease Models Reduces colonic inflammation 55–65% in DSS-induced colitis; oral administration viable; minimal systemic effects Reduces inflammation 30–40% but requires parenteral routes; systemic immune modulation may confound localized end

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Inflammatory Bowel Disease Models
  • Reduces colonic inflammation 55–65% in DSS-induced colitis; oral administration viable; minimal systemic effects
  • Reduces inflammation 30–40% but requires parenteral routes; systemic immune modulation may confound localized endpoints
  • KPV superior for isolated GI studies
  • Rheumatoid Arthritis / Autoimmune Models
  • Limited efficacy. No systemic Treg expansion; does not shift Th1/Th2 balance
  • Reduces joint swelling 40–50%; increases Treg populations 2–3×; modulates systemic autoimmunity
  • VIP required for systemic autoimmune protocols
  • Dermatological Inflammation (Psoriasis, Dermatitis)
  • Direct MC1R activation on keratinocytes; topical application effective; reduces epidermal TNF-α 50–60%
  • Less effective topically due to poor skin penetration; systemic administration affects inflammation but with broader off-target effects
  • KPV preferred for localized dermal studies
  • Sepsis / Acute Systemic Inflammation
  • Minimal effect on mortality or systemic cytokine storm; peripheral action insufficient
  • Reduces mortality 30–40% in LPS-induced sepsis models; modulates systemic cytokine release
  • VIP essential for acute systemic inflammation
  • Neuroprotection / CNS Inflammation
  • Poor BBB penetration; ineffective for microglial activation or neuroinflammation
  • Crosses BBB; reduces microglial activation 40–55%; neuroprotective in ischemia models
  • VIP required for CNS research applications
  • Cost and Accessibility
  • Synthesis cost: $180–$250 per gram; stable at room temperature 6–8 weeks
  • Synthesis cost: $450–$700 per gram; requires −20°C storage; rapid degradation at ambient temp
  • KPV more practical for budget-limited studies